Hepatic Steatosis in HIV-HCV Coinfected Patients
Author Information
Author(s): Verma Sumita, Goldin Robert D, Main Janice
Primary Institution: Imperial College at St Mary's Hospital, London, UK
Hypothesis
Is hepatic steatosis associated with antiretroviral therapy and more advanced hepatic fibrosis in patients with HIV-HCV coinfection?
Conclusion
Hepatic steatosis is associated with more advanced hepatic fibrosis in HIV-HCV coinfected patients, and HAART therapy is linked to a lower prevalence of steatosis.
Supporting Evidence
- 58% of HIV-HCV coinfected patients showed evidence of hepatic steatosis.
- Patients receiving HAART only had a lower prevalence of steatosis compared to those on NRTIs only or sequential therapy.
- 45% of the patients had advanced fibrosis, with steatosis being an independent predictor.
Takeaway
Many people with both HIV and hepatitis C have a liver problem called steatosis, which is linked to more serious liver damage. Taking certain medications can help reduce this problem.
Methodology
The study retrospectively identified HIV-HCV coinfected patients from a clinic and assessed their liver biopsies for steatosis and fibrosis using specific scoring methods.
Potential Biases
Selection bias due to the retrospective nature and the specific criteria for liver biopsy inclusion.
Limitations
The study's retrospective design and small sample size may limit the generalizability of the findings.
Participant Demographics
{"mean_age":39.4,"gender_distribution":{"male":54,"female":6},"ethnicity":{"white":24,"other_european":24,"others":12}}
Statistical Information
P-Value
0.044
Confidence Interval
95% CI 1.0–20.4
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website